Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer

BUFFALO, NY--(Marketwired - May 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Langdon L. Miller, M.D., as President and Chief Medical Officer, effective...
April 30, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Report First Quarter 2015 Financial Results on May 6

BUFFALO, NY--(Marketwired - Apr 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on May 6, 2015, it will report its financial results for the first quarter ended March...
April 29, 2015 09:54 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Enters Into Agreement to Raise Up to $4 Million Through Sales of Equity Stake in Incuron Joint Venture

BUFFALO, NY--(Marketwired - Apr 29, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into an agreement to sell its equity stake in Incuron, LLC (Incuron) to Dr....
April 27, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod

BUFFALO, NY--(Marketwired - Apr 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the award of a three-year, $1.2 million Breast Cancer...
April 22, 2015 09:12 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO

BUFFALO, NY--(Marketwired - Apr 22, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that findings from a Phase 1 clinical study of entolimod (previously known as CBLB502) have been...
April 14, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure

BUFFALO, NY--(Marketwired - Apr 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that a second proposal application to support further development...
April 02, 2015 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612

BUFFALO, NY--(Marketwired - Apr 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of a U.S. patent application, to issue as U.S. Patent No. 9,006,183, covering...
March 16, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation

BUFFALO, NY--(Marketwired - Mar 16, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1...
March 02, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent

BUFFALO, NY--(Marketwired - Mar 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a...
February 24, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports Fourth Quarter and Fiscal 2014 Financial Results and Development Progress

BUFFALO, NY--(Marketwired - Feb 24, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December...